Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GRI Bio Inc GRI

Healthcare Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in... see more

Recent & Breaking News (NDAQ:GRI)

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire 13 days ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GlobeNewswire November 14, 2024

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GlobeNewswire October 24, 2024

GRI Bio Announces Exercise of Warrants

GlobeNewswire October 21, 2024

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire October 16, 2024

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GlobeNewswire October 7, 2024

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GlobeNewswire September 30, 2024

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GlobeNewswire September 26, 2024

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GlobeNewswire September 25, 2024

GRI Bio Participates in Virtual Investor KOL Connect Segment

GlobeNewswire September 18, 2024

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

GRI Bio to Present at the 2024 European Respiratory Congress

GlobeNewswire September 4, 2024

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2024

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GlobeNewswire July 15, 2024

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment

GlobeNewswire July 11, 2024

GRI Bio Regains Compliance with Nasdaq

GlobeNewswire July 8, 2024

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GlobeNewswire July 2, 2024

GRI Bio to Present at the 8th Annual IPF Summit

GlobeNewswire July 1, 2024

GRI Bio Announces Closing of $4.0 Million Public Offering

GlobeNewswire June 28, 2024

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GlobeNewswire June 27, 2024